LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

3.18 -7.83

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.17

Max

3.54

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.6M -38M
Verkäufe	1.6M 11M
Gewinnspanne	-333.127
Angestellte	144
EBITDA	-1.8M -35M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+194.8% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	110M 605M
Vorheriger Eröffnungskurs	11.01
Vorheriger Schlusskurs	3.18

Nachrichtenstimmung

By Acuity

50%

183 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.06 / 1.23 Unterstützung & Widerstand

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

15. Sept. 2025, 22:39 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15. Sept. 2025, 16:43 UTC

Wichtige Markttreiber

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15. Sept. 2025, 16:42 UTC

Wichtige Markttreiber

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15. Sept. 2025, 16:35 UTC

Wichtige Markttreiber

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15. Sept. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15. Sept. 2025, 23:34 UTC

Market Talk

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15. Sept. 2025, 22:48 UTC

Market Talk

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15. Sept. 2025, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Expects Commercial Launch in 2029

15. Sept. 2025, 22:12 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15. Sept. 2025, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15. Sept. 2025, 22:11 UTC

Akquisitionen, Fusionen, Übernahmen

CSL to Have Right to Exercise Option Based on Phase 3 Data

15. Sept. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15. Sept. 2025, 21:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15. Sept. 2025, 21:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15. Sept. 2025, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15. Sept. 2025, 21:14 UTC

Akquisitionen, Fusionen, Übernahmen

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15. Sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Sept. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15. Sept. 2025, 19:14 UTC

Market Talk

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15. Sept. 2025, 18:16 UTC

Market Talk

Gold Powers to New High -- Market Talk

15. Sept. 2025, 18:05 UTC

Market Talk

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15. Sept. 2025, 17:50 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15. Sept. 2025, 17:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2025, 17:10 UTC

Market Talk

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15. Sept. 2025, 16:52 UTC

Market Talk

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15. Sept. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

15. Sept. 2025, 16:20 UTC

Market Talk

Ergebnisse

Auto & Transport Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

194.8% Vorteil

12-Monats-Prognose

Durchschnitt 10.2 USD 194.8%

Hoch 15 USD

Tief 6 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.06 / 1.23Unterstützung & Widerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Stimmung

By Acuity

183 / 371 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.